CN1678611A - 氮杂-双环烷基醚及其作为α7-NACHR激动剂的用途 - Google Patents
氮杂-双环烷基醚及其作为α7-NACHR激动剂的用途 Download PDFInfo
- Publication number
- CN1678611A CN1678611A CNA038207303A CN03820730A CN1678611A CN 1678611 A CN1678611 A CN 1678611A CN A038207303 A CNA038207303 A CN A038207303A CN 03820730 A CN03820730 A CN 03820730A CN 1678611 A CN1678611 A CN 1678611A
- Authority
- CN
- China
- Prior art keywords
- aza
- acid salt
- phenyl
- salt form
- free alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实施例 | 立体化学 | X | R | HPLCrt(分) | [α]rt D | mp.℃(盐) | M+H+ |
2 | (3R,4S) | 键 | 苯基 | 5.7 | -23.5°(0.1%MeOH) | 143-145(非盐) | 268 |
3 | (3S,4R) | 键 | 苯基 | 5.7 | -26.5°(0.1%MeOH) | 145-147(非盐) | 268 |
4 | (S) | CH2 | 苯基 | 5.2 | -32.5°(0.5%MeOH) | 128-130(非盐) | 282.2 |
5 | (R) | CH2 | 4-氯-苯基 | 6.2 | +29.0°(0.1%MeOH) | 175-177(非盐) | 316.2 |
6 | (R) | CH2 | 3-氯-苯基 | 6.2 | +38.5°(0.1%MeOH) | 98-100(非盐) | 316.2 |
7 | rac. | CH2 | 2-甲氧基-苯基 | 5.5 | N/A | 125-128(非盐) | 312.4 |
8 | (R) | CH2 | 4-三氟甲基-苯基 | 7.0 | +28(0.1%MeOH) | 172-175(非盐) | 350.5 |
9 | (R) | CH2 | 2-氟-苯基 | 5.6 | +23.5°(0.1%MeOH) | 110-113(非盐) | 300.2 |
10 | (R) | CH2 | 2-氯-苯基 | 5.7 | +29.5°(0.1%MeOH) | 85-87(非盐) | 316.2 |
11 | (R) | CH2 | 4-氟-苯基 | 5.7 | +39.5°(0.1%MeOH) | 146-149(非盐) | 300.2 |
12 | (R) | CH2 | 3-氟-苯基 | 5.5 | +31.5°(0.1%MeOH) | 118-121(非盐) | 300.2 |
13 | (R) | CH2 | 3,4-二氯-苯基 | 7.3 | +29.5°(0.1%MeOH) | 173-175(非盐) | 350.2 |
14 | (R) | CH2 | 3-三氟甲基-苯基 | 6.9 | +23.0°(0.1%MeOH) | 112-115(非盐) | 350.3 |
15 | (R) | CH2 | 3,5-二氯-苯基 | 7.3 | +31.0°(0.1%MeOH) | 127-130(非盐) | 350.2 |
16 | (R) | CH2 | 1-异苯并呋喃基 | 6.8 | +29.0(0.1%MeOH) | 193-195°(非盐) | 321.38 |
实施例 | 立体化学 | X | R | HPLCrt(分) | [α]rt D | mp.℃(盐) | M+H+ |
19 | (S) | CH2 | 苯基 | 5.6 | -31.0°(0.95%MeOH) | 126-129 | 282.2 |
(非盐) | |||||||
20 | rac. | CH2 | 2-氟-苯基 | 5.9 | N/A | 87-93(非盐) | 300.2 |
21 | rac. | CH2 | 3-氯-苯基 | 6.6 | N/A | 163-165(非盐) | 316.2 |
22 | rac. | CH2 | 3,4-二氯-苯基 | 3.6 | N/A | 182-184(非盐) | 350.1 |
23 | rac. | CH2 | 2,4-二氯-苯基 | 3.6 | N/A | N/A(油)(HCl盐) | 350.1 |
24 | rac. | CH2 | 3,5-二氯-苯基 | 3.7 | N/A | 183-184(非盐) | 350.1 |
25 | rac. | CH2 | 3-氰基-苯基 | 3.5 | N/A | 189(非盐) | 307.2 |
26 | rac. | CH2 | 3-三氟甲基-苯基 | 3.5 | N/A | 158-159(非盐) | 350.2 |
27 | rac. | CH2 | 苯并[1,3]间二氧杂环戊烯-5-基 | 5.9 | N/A | nd(非盐) | 326.2 |
28 | (R) | CH2 | 2-氟-苯基 | 5.7 | nd | nd(非盐) | 300.2 |
29 | rac. | CH2 | 3,5-二-三氟-甲基-苯基 | 7.6 | N/A | nd(非盐) | 418.2 |
30 | (R) | CH2 | 2-氯-苯基 | 3.4 | +29.6°(0.50%EtOH) | nd(非盐) | 316.2 |
31 | (R) | CH2 | 3-氯-苯基 | 3.4 | nd | 160-163(非盐) | 316.2 |
32 | (R) | CH2 | 噻吩(thiophen)-2-基 | 5.2 | nd | nd(非盐) | 288.1 |
33 | (R) | CH2 | 萘-1-基 | 6.8 | nd | nd(非盐) | 332.2 |
34 | rac. | CH2 | 4-氯-苯基 | 3.5 | N/A | 170-173(非盐) | 316.2 |
35 | (R) | CH2 | 苯并呋喃-2-基 | 6.9 | +33.8°(0.97%MeOH) | 183-186(非盐) | 322.2 |
36 | (R) | CH2 | 噻吩-3-基 | 5.3 | +26.2°(0.99%MeOH) | 167-174(非盐) | 288.1 |
37 | (R) | CH2 | 萘-2-基 | 7.0 | +27.0°(0.1%MeOH) | 170-190(非盐) | 332.2 |
38 | (R) | CH2 | 2,3-二氯-苯基 | 6.9 | nd | nd(非盐) | 350.1 |
39 | (R) | CH2 | 2,3-二氟-苯基 | 3.3 | +33.7°(0.5%MeOH) | 135-136(非盐) | 318.2 |
40 | rac | CH2 | 2-甲氧基-苯基 | 3.4 | N/A | 160-163(非盐) | 312.2 |
41 | (R) | CH2 | 2,6-二氯-苯基 | nd | nd | nd(非盐) | 350 |
42 | (R) | CH2 | 3-氟-苯基 | nd | nd | nd(非盐) | 300 |
43 | (R) | CH2 | 呋喃-3-基 | nd | nd | nd(非盐) | 272 |
44 | (R) | CH2 | 呋喃-2-基 | 3.2 | nd | nd(非盐) | 272.2 |
45 | (R) | CH2 | 2,5-二氟-苯基 | 4.1 | +24.7°(0.525%MeOH) | nd(非盐) | 318.3 |
46 | (R) | CH2 | 2,5-二氯-苯基 | 5.3 | +19.9°(0.525%MeOH) | nd(非盐) | 350.2 |
47 | (R) | CH2 | 2-三氟甲基-苯基 | 3.5 | nd | 187-207(非盐) | 350.2 |
48 | (R) | CH2 | 邻-甲苯基 | 4.4 | nd | 85-94(非盐) | 296.2 |
49 | (R) | CH2 | 间-甲苯基 | 3.4 | +33.1°(0.52%MeOH) | 139-140(非盐) | 296.2 |
50 | (R) | CH2 | 对-甲苯基 | 4.7 | +28.6°(0.54%MeOH) | 158-164(非盐) | 296.2 |
51 | (R) | CH2 | 5-氟-2-甲氧基-苯基 | 4.5 | +25.5°(0.55%MeOH) | 115-118(非盐) | 330.2 |
52 | (R) | CH2 | 2-氟-4-甲基- 苯基 | 4.9 | +30.2°(0.54%MeOH) | 130-132(非盐) | 314.2 |
53 | (R) | CH2 | 2-氟-5-甲基-苯基 | 4.8 | +30.3°(0.53%MeOH) | 135-145(非盐) | 314.2 |
54 | (R) | CH2 | 3,4-二甲基-苯基 | 3.5 | +31.5°(0.50%MeOH) | 154-156(非盐) | 310.2 |
55 | (R) | CH2 | 2-氯-4-甲基-苯基 | 3.5 | +29.6°(0.52%MeOH) | 114-116(非盐) | 330.0 |
56 | (R) | singlebond | 2-氟-4-甲基-苯基 | 3.4 | nd | 126-130(非盐) | 300.2 |
57 | (R) | CH2 | 2-氯-5-甲基-苯基 | 3.5 | nd | nd(非盐) | 330.3 |
实施例 | 立体化学 | X | R | HPLCrt(分) | [α]rt D | mp.℃ | M+H+ |
76 | (R) | CH2 | 4,5-二甲基-2-氟-苯基 | 5.5 | +36°(0.1%MeOH) | 108-110 | 328.3 |
77 | (R) | CH2 | 4-乙基苯基 | 5.7 | +25°(0.1% | 148-150 | 310.2 |
MeOH) | |||||||
78 | (R) | CH2 | 2-氟-5-三氟甲基-苯基 | 6.9 | +37°(0.5%MeOH) | 138-140 | 368.2 |
79 | (R) | CH2 | 3,4-OCH2O-苯基 | 5.6 | +49°(0.1%MeOH) | 180-182 | 326.2 |
80 | (R) | CH2 | 3-甲氧基-苯基 | 5.8 | +36°(0.1%MeOH) | 142-144 | 312.2 |
81 | (R) | CH2 | 2-氟-4-甲氧基-苯基 | 4.4 | +28°(0.1%MeOH) | 118-120 | 330.3 |
82 | (R) | CH2 | 4-二氟甲氧基-苯基 | 4.8 | +27°(0.1%MeOH) | 153-155 | 348.3 |
83 | (R) | CH2 | 4-甲氧基-苯基 | 5.8 | +58°(0.1%MeOH) | 154-156 | 312.2 |
84 | (R) | CH2 | 4-异丙基-苯基 | 5.7 | +53°(0.1%MeOH) | 164-166 | 324.29 |
实施例 | 立体化学 | X | R |
85a | (R) | CH2 | 3,4-二甲基-苯基 |
85b | (R) | CH2 | 4-甲基-苯基 |
85c | (R) | CH2 | 3-甲基-苯基 |
85d | (R) | CH2 | 2,5-二氟-4-甲基-苯基 |
85e | (R) | CH2 | 2-氟-5-甲基-苯基 |
85f | (R) | CH2 | 3-三氟甲氧基-苯基 |
85g | (3R,4S) | 键 | 2-氟-4-甲基-苯基 |
85h | (3S,4R) | 键 | 2-氟-4-甲基-苯基 |
85i | (R) | CH2 | 2,5-二氟-苯基 |
85j | (R) | CH2 | 4-正丙基-苯基 |
85k | (R) | CH2 | 2-氯-4-甲基-苯基 |
85l | (R) | CH2 | 茚满-5-基 |
85m | (R) | CH2 | 2-噻吩基 |
85n | (R) | CH2 | 6-1,2,3,4-四氢萘基 |
85o | (R) | CH2 | 2-萘基 |
85p | (R) | CH2 | 2-苯并噻吩基 |
85q | (R) | CH2 | 3-噻吩基 |
85r | (R) | CH2 | 1-萘基 |
Claims (14)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0220581.3 | 2002-09-04 | ||
GB0220581A GB0220581D0 (en) | 2002-09-04 | 2002-09-04 | Organic Compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1678611A true CN1678611A (zh) | 2005-10-05 |
CN1325493C CN1325493C (zh) | 2007-07-11 |
Family
ID=9943515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038207303A Expired - Lifetime CN1325493C (zh) | 2002-09-04 | 2003-09-03 | 氮杂-双环烷基醚及其作为α7-NACHR激动剂的用途 |
Country Status (26)
Country | Link |
---|---|
US (8) | US20060167002A1 (zh) |
EP (3) | EP2100893A1 (zh) |
JP (2) | JP4348422B2 (zh) |
KR (2) | KR20070058027A (zh) |
CN (1) | CN1325493C (zh) |
AT (1) | ATE448225T1 (zh) |
AU (1) | AU2003260486C1 (zh) |
BR (2) | BRPI0314325B8 (zh) |
CA (1) | CA2495685C (zh) |
CY (1) | CY1109765T1 (zh) |
DE (1) | DE60330015D1 (zh) |
DK (1) | DK1537104T3 (zh) |
EC (1) | ECSP055621A (zh) |
ES (1) | ES2336099T3 (zh) |
GB (1) | GB0220581D0 (zh) |
HK (2) | HK1077822A1 (zh) |
IL (2) | IL166918A (zh) |
MX (1) | MXPA05002546A (zh) |
NO (1) | NO331556B1 (zh) |
NZ (1) | NZ538534A (zh) |
PL (1) | PL209425B1 (zh) |
PT (1) | PT1537104E (zh) |
RU (1) | RU2352569C2 (zh) |
SI (1) | SI1537104T1 (zh) |
WO (1) | WO2004022556A1 (zh) |
ZA (1) | ZA200500816B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101331132A (zh) * | 2005-12-16 | 2008-12-24 | 诺瓦提斯公司 | 作为n-achr的胆碱能配体用于治疗精神病和神经变性疾病的[(1h-吲哚-5-基)-杂芳氧基]-(1-氮杂-二环[3.3.1]壬烷 |
CN103442701A (zh) * | 2011-01-27 | 2013-12-11 | 诺瓦提斯公司 | 烟碱乙酰胆碱受体α7激活剂的用途 |
CN103561740A (zh) * | 2011-03-18 | 2014-02-05 | 诺瓦提斯公司 | 用于帕金森病中多巴胺诱导的运动障碍的α7烟碱性乙酰胆碱受体活化剂和mGluR5拮抗剂的组合 |
CN103717596A (zh) * | 2011-07-15 | 2014-04-09 | 诺华股份有限公司 | 氮杂-二环二芳基醚的盐以及制备它们或它们的前体的方法 |
CN103930112A (zh) * | 2011-10-20 | 2014-07-16 | 诺华股份有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂疗法的响应的生物标志物 |
CN104837499A (zh) * | 2012-12-11 | 2015-08-12 | 诺华有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物 |
CN105246485A (zh) * | 2013-01-15 | 2016-01-13 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂的应用 |
CN105263492A (zh) * | 2013-01-15 | 2016-01-20 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
CN105263495A (zh) * | 2013-01-15 | 2016-01-20 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂的应用 |
CN110051670A (zh) * | 2009-09-22 | 2019-07-26 | 诺华股份有限公司 | 烟碱乙酰胆碱受体α7激活剂的用途 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
EP1656375B1 (en) | 2003-08-13 | 2011-01-19 | NeuroSearch A/S | Novel quinuclidine derivatives and their pharmaceutical use |
US20050137203A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US20050137217A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
US20050137398A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
GB0415746D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
US7829712B2 (en) * | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
CN101083993A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
CN1922176A (zh) * | 2004-12-10 | 2007-02-28 | 艾博特公司 | 稠合的双环杂环取代的奎宁环衍生物 |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
EP1987032A1 (en) | 2006-02-14 | 2008-11-05 | NeuroSearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
DE602007004307D1 (de) * | 2006-02-16 | 2010-03-04 | Neurosearch As | Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin-rezeptorliganden |
MX2009001875A (es) | 2006-08-21 | 2009-03-02 | Genentech Inc | Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. |
RU2010107462A (ru) * | 2007-08-02 | 2011-09-10 | Таргасепт, Инк. (Us) | ЛЕЧЕНИЕ α7-СЕЛЕКТИВНЫМИ ЛИГАНДАМИ |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
CA2727250A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
RU2495028C2 (ru) | 2008-07-01 | 2013-10-10 | Дженентек, Инк. | Изоиндолоны и способы их применения |
ES2396300T3 (es) | 2008-11-19 | 2013-02-20 | Envivo Pharmaceuticals, Inc. | Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma |
CN102802620A (zh) * | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
JP2012533601A (ja) * | 2009-07-23 | 2012-12-27 | ノバルティス アーゲー | 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−2−オン誘導体の使用 |
BR112012008518A2 (pt) | 2009-10-13 | 2016-04-05 | Msd Oss Bv | derivado heterocíclico, e, composição farmacêutica |
WO2011146511A1 (en) | 2010-05-17 | 2011-11-24 | Envivo Pharmaceuticals, Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
US20150313884A1 (en) * | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
EP4251158A1 (en) | 2020-11-25 | 2023-10-04 | Vanda Pharmaceuticals Inc. | Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist |
WO2023213740A1 (en) * | 2022-05-05 | 2023-11-09 | Philip Morris Products S.A. | Nicotinic acetylcholine receptor ligands |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB809574A (en) | 1956-01-26 | 1959-02-25 | Gasaccumulator Svenska Ab | Improvements in or relating to electrical signal light systems |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
ES2053451T3 (es) | 1986-01-07 | 1994-08-01 | Beecham Group Plc | Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles. |
KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
DE3854932T2 (de) | 1987-04-15 | 1996-06-13 | Beecham Group Plc | Am Brückenkopf substituierte Azabicyclenderivate |
CA1307790C (en) | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
GB8718445D0 (en) | 1987-08-04 | 1987-09-09 | Wyeth John & Brother Ltd | Pyridyl-ethers |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
DE8817121U1 (de) | 1988-11-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Quinuclidine |
GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
CA2002182C (en) | 1989-11-03 | 2000-06-13 | Richard J. Wurtman | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
DE4116582A1 (de) | 1990-05-19 | 1991-11-21 | Boehringer Ingelheim Kg | Bicyclische 1-aza-cycloalkane |
YU84791A (sh) | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | Biciklicni 1-aza-cikloalkalni |
KR930702312A (ko) | 1990-08-31 | 1993-09-08 | 아만 히데아키 | 피리미딘 유도체 및 의약 |
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
WO1992015579A1 (en) | 1991-03-08 | 1992-09-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5385912A (en) * | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−3−カルボン酸誘導体 |
WO1993021184A1 (en) | 1992-04-10 | 1993-10-28 | Zeneca Limited | Biphenylylquinuclidine derivatives as squalene synthase inhibitors |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
AU7394394A (en) | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
WO1994018201A1 (en) | 1993-02-12 | 1994-08-18 | Sankyo Company, Limited | Isoxazoleoxy derivative |
JPH06293768A (ja) | 1993-02-12 | 1994-10-21 | Sankyo Co Ltd | イソオキサゾールオキシ誘導体 |
JP4208267B2 (ja) | 1993-07-30 | 2009-01-14 | キヤノン株式会社 | 制御装置 |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
JPH11512443A (ja) | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ環式またはアザ二環式化合物 |
SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
ATE254618T1 (de) | 1997-05-30 | 2003-12-15 | Neurosearch As | Spiro chinuclidin-derivate, ihre herstellung und verwendung |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
BR0012793A (pt) | 1999-07-28 | 2002-04-30 | Univ Leland Stanford Junior | Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina |
SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
WO2001066546A1 (fr) | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Composes spiro, leur procede de preparation et leur utilisation comme medicaments |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1−アザビシクロアルカン化合物およびその医薬用途 |
US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
BR0213760A (pt) | 2001-10-26 | 2004-10-19 | Upjohn Co | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição |
DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
JP2005525357A (ja) | 2002-02-20 | 2005-08-25 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α7ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物 |
DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
WO2004016608A1 (en) | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
EE05516B1 (et) | 2002-09-25 | 2012-02-15 | Memory@Pharmaceuticals@Corporation | Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine |
WO2004039321A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
WO2004039366A1 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
EP1562959A2 (en) | 2002-11-01 | 2005-08-17 | Pharmacia & Upjohn Company LLC | Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases |
ATE345342T1 (de) | 2002-11-11 | 2006-12-15 | Neurosearch As | 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung |
CN1726033A (zh) | 2002-12-11 | 2006-01-25 | 法马西亚和厄普乔恩公司 | 用α7烟碱乙酰胆碱受体激动剂和其它化合物的联合治疗疾病 |
EP1587511A2 (en) | 2003-01-22 | 2005-10-26 | Pharmacia & Upjohn Company LLC | Treatment of diseases with alpha-7 nach receptor full agonists |
WO2005013910A2 (en) | 2003-08-07 | 2005-02-17 | University Of South Florida | Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors |
JP4226981B2 (ja) | 2003-09-24 | 2009-02-18 | 三井金属鉱業株式会社 | プリント配線板の製造方法及びその製造方法で得られたプリント配線板 |
US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20070060588A1 (en) | 2003-12-22 | 2007-03-15 | Jianguo Ji | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137204A1 (en) | 2003-12-22 | 2005-06-23 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
BRPI0418092A (pt) | 2003-12-23 | 2007-04-17 | Pfizer Prod Inc | combinação terapêutica para melhora cognitiva e transtornos psicóticos |
JP5019884B2 (ja) | 2004-02-20 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 炎症プロセスおよび転移プロセスの調節 |
KR20070030196A (ko) | 2004-04-13 | 2007-03-15 | 이카겐, 인코포레이티드 | 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘 |
US7514450B2 (en) | 2004-05-19 | 2009-04-07 | Neurosearch A/S | Azabicyclic aryl derivatives |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
US7652010B2 (en) | 2004-10-15 | 2010-01-26 | Neurosearch A/S | Azabicyclic aryl derivatives and their medical use |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
CN1922176A (zh) | 2004-12-10 | 2007-02-28 | 艾博特公司 | 稠合的双环杂环取代的奎宁环衍生物 |
EP1866314B1 (en) | 2005-02-16 | 2010-09-15 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
WO2006101745A2 (en) | 2005-03-18 | 2006-09-28 | Abbott Laboratories | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
EP1907367A4 (en) | 2005-04-18 | 2011-05-11 | Saeed R Khan | DEVELOPMENT AND SYNTHESIS OF NEW TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYL HARVEST (BPU) SULFUR ANALOGUE |
FR2884822B1 (fr) | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
GB0508314D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
TW201004961A (en) | 2005-06-14 | 2010-02-01 | Schering Corp | Aspartyl protease inhibitors |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
EP2341121B1 (en) | 2008-10-17 | 2015-05-27 | Nok Klüber Co., Ltd. | Lubricating grease composition and manufacturing method therefor |
-
2002
- 2002-09-04 GB GB0220581A patent/GB0220581D0/en not_active Ceased
-
2003
- 2003-09-03 CA CA 2495685 patent/CA2495685C/en not_active Expired - Lifetime
- 2003-09-03 ES ES03793791T patent/ES2336099T3/es not_active Expired - Lifetime
- 2003-09-03 JP JP2004533455A patent/JP4348422B2/ja not_active Expired - Lifetime
- 2003-09-03 EP EP20090164576 patent/EP2100893A1/en not_active Withdrawn
- 2003-09-03 EP EP20030793791 patent/EP1537104B1/en not_active Expired - Lifetime
- 2003-09-03 RU RU2005109913A patent/RU2352569C2/ru active
- 2003-09-03 AT AT03793791T patent/ATE448225T1/de active
- 2003-09-03 NZ NZ538534A patent/NZ538534A/en not_active IP Right Cessation
- 2003-09-03 DK DK03793791T patent/DK1537104T3/da active
- 2003-09-03 BR BRPI0314325A patent/BRPI0314325B8/pt active IP Right Grant
- 2003-09-03 PT PT03793791T patent/PT1537104E/pt unknown
- 2003-09-03 SI SI200331746T patent/SI1537104T1/sl unknown
- 2003-09-03 WO PCT/EP2003/009772 patent/WO2004022556A1/en active IP Right Grant
- 2003-09-03 DE DE60330015T patent/DE60330015D1/de not_active Expired - Lifetime
- 2003-09-03 EP EP20100184187 patent/EP2308876A1/en not_active Withdrawn
- 2003-09-03 CN CNB038207303A patent/CN1325493C/zh not_active Expired - Lifetime
- 2003-09-03 PL PL374013A patent/PL209425B1/pl unknown
- 2003-09-03 KR KR1020077011698A patent/KR20070058027A/ko not_active Application Discontinuation
- 2003-09-03 KR KR20057003665A patent/KR100808324B1/ko active IP Right Review Request
- 2003-09-03 US US10/526,759 patent/US20060167002A1/en not_active Abandoned
- 2003-09-03 AU AU2003260486A patent/AU2003260486C1/en not_active Expired
- 2003-09-03 MX MXPA05002546A patent/MXPA05002546A/es active IP Right Grant
- 2003-09-03 BR BR122014026685-5A patent/BR122014026685B1/pt not_active IP Right Cessation
-
2005
- 2005-01-27 ZA ZA200500816A patent/ZA200500816B/xx unknown
- 2005-02-15 IL IL16691805A patent/IL166918A/en active IP Right Grant
- 2005-02-22 EC ECSP055621 patent/ECSP055621A/es unknown
- 2005-04-01 NO NO20051626A patent/NO331556B1/no not_active IP Right Cessation
- 2005-11-07 HK HK05109896A patent/HK1077822A1/xx not_active IP Right Cessation
- 2005-11-30 HK HK05110918A patent/HK1078868A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,312 patent/US7579362B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 US US12/262,896 patent/US8236803B2/en not_active Expired - Lifetime
-
2009
- 2009-02-19 JP JP2009036918A patent/JP5124714B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-10 CY CY101100129T patent/CY1109765T1/el unknown
-
2012
- 2012-05-02 US US13/462,187 patent/US9012451B2/en not_active Expired - Lifetime
-
2013
- 2013-02-28 IL IL225002A patent/IL225002A/en active IP Right Grant
-
2015
- 2015-03-10 US US14/643,275 patent/US9567343B2/en not_active Expired - Lifetime
-
2017
- 2017-01-04 US US15/398,427 patent/US9849117B2/en not_active Expired - Lifetime
- 2017-11-21 US US15/819,535 patent/US20180078536A1/en not_active Abandoned
-
2018
- 2018-11-15 US US16/191,693 patent/US20190083474A1/en not_active Abandoned
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101331132B (zh) * | 2005-12-16 | 2013-12-04 | 诺瓦提斯公司 | 作为n-achr的胆碱能配体用于治疗精神病和神经变性疾病的[(1h-吲哚-5-基)-杂芳氧基]-(1-氮杂-二环[3.3.1]壬烷 |
CN101331132A (zh) * | 2005-12-16 | 2008-12-24 | 诺瓦提斯公司 | 作为n-achr的胆碱能配体用于治疗精神病和神经变性疾病的[(1h-吲哚-5-基)-杂芳氧基]-(1-氮杂-二环[3.3.1]壬烷 |
US11096916B2 (en) | 2009-09-22 | 2021-08-24 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
CN110051670A (zh) * | 2009-09-22 | 2019-07-26 | 诺华股份有限公司 | 烟碱乙酰胆碱受体α7激活剂的用途 |
US10537539B2 (en) | 2009-09-22 | 2020-01-21 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
CN103442701A (zh) * | 2011-01-27 | 2013-12-11 | 诺瓦提斯公司 | 烟碱乙酰胆碱受体α7激活剂的用途 |
CN103561740A (zh) * | 2011-03-18 | 2014-02-05 | 诺瓦提斯公司 | 用于帕金森病中多巴胺诱导的运动障碍的α7烟碱性乙酰胆碱受体活化剂和mGluR5拮抗剂的组合 |
CN103717596A (zh) * | 2011-07-15 | 2014-04-09 | 诺华股份有限公司 | 氮杂-二环二芳基醚的盐以及制备它们或它们的前体的方法 |
CN103717596B (zh) * | 2011-07-15 | 2017-11-21 | 诺华股份有限公司 | 氮杂‑二环二芳基醚的盐以及制备它们或它们的前体的方法 |
CN107602552A (zh) * | 2011-07-15 | 2018-01-19 | 诺华股份有限公司 | 氮杂‑二环二芳基醚的盐以及制备它们或它们的前体的方法 |
CN103930112A (zh) * | 2011-10-20 | 2014-07-16 | 诺华股份有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂疗法的响应的生物标志物 |
CN103930112B (zh) * | 2011-10-20 | 2018-11-09 | 诺华股份有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂疗法的响应的生物标志物 |
CN104837499A (zh) * | 2012-12-11 | 2015-08-12 | 诺华有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物 |
TWI670061B (zh) * | 2012-12-11 | 2019-09-01 | 瑞士商諾華公司 | 可預測對α7菸鹼型乙醯膽鹼受體活化劑治療之反應性之生物標記 |
CN105263492A (zh) * | 2013-01-15 | 2016-01-20 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
CN105246485B (zh) * | 2013-01-15 | 2019-03-15 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂的应用 |
CN105263492B (zh) * | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
CN105263495A (zh) * | 2013-01-15 | 2016-01-20 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂的应用 |
CN105246485A (zh) * | 2013-01-15 | 2016-01-13 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1678611A (zh) | 氮杂-双环烷基醚及其作为α7-NACHR激动剂的用途 | |
CN1034865C (zh) | 2-氨基嘧啶酮的制备方法 | |
EP2217597B1 (en) | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease | |
CN1662541A (zh) | 呋喃基化合物 | |
CN1211983A (zh) | 用于治疗的氨基甲酸的氮杂双环酯 | |
CN1015057B (zh) | 哌嗪基-杂环化合物的制备方法 | |
CN1400969A (zh) | 稠合的咪唑鎓衍生物 | |
CN1771234A (zh) | 吡咯并三嗪激酶抑制剂的制备方法 | |
CN1784230A (zh) | 烟碱性乙酰胆碱受体的正向调节剂 | |
CN1756757A (zh) | 吡咯并咪唑衍生物、其制备、包含它们的药物组合物及其作为向精神剂的应用 | |
WO2013114173A1 (en) | A novel process for the preparation of sitagliptin | |
CN1211974A (zh) | 喹啉-2-(1h)-酮 | |
US8765668B2 (en) | Methods of synthesis of β-aminobutyryl substituted compounds | |
TW200831478A (en) | Chromane derivatives, synthesis thereof, and intermediates thereto | |
CN1845907A (zh) | 胍衍生物 | |
CN1914200A (zh) | 烟碱性乙酰胆碱受体配件 | |
CN102796105A (zh) | 2,5,6,7-四氢吡咯并[3,4-c]哒嗪-3-酮及其衍生物以及它们的合成方法 | |
KR20110132565A (ko) | N-〔(2-아자-비시클로〔2.1.1〕헥스-1-일)-아릴-메틸〕-헤테로벤즈아미드의 유도체, 그의 제조 방법 및 그의 치료 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1077822 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Feuerbach Dominik Inventor after: K. Hulter Inventor after: Ritchie Timothy John Inventor after: Bouhelal Rochdi Inventor before: Feuerbach Dominik Inventor before: K. Hulter Inventor before: Ritchie Timothy John |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FEUERBACH DOMINIK HURTH KONSTANZE RITCHIE TIMOTHY JOHN TO: FEUERBACH DOMINIK HURTH KONSTANZE RITCHIE TIMOTHY JOHN BOUHELAL ROCHDI |
|
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: Novartis AG |
|
CX01 | Expiry of patent term |
Granted publication date: 20070711 |
|
CX01 | Expiry of patent term |